Document text
Principal Investigator: Robbie B Mailliard
Organization: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
Fiscal Year: 2024
Award: $739,018
Funding agency: National Institute of Allergy and Infectious Diseases
ABSTRACT
The CDC recommends that persons living with HIV (PWH) be vaccinated against SARS-CoV-2. However,
there are minimal scientific data to support this important public health principle in relation to ongoing
immune dysfunction and chronic comorbidities and the persistent HIV reservoir in antiretroviral treated (ART)
PWH. We propose that a formal, comprehensive, longitudinal study in a well-characterized cohort of male
and female PWH compared to HIV uninfected controls (HUC) is essential to assess the immunogenicity
of COVID-19 vaccines in PWH. The MACS-WIHS Combined Cohort Study (MWCCS) is ideal for analyzing
the interactive impact of chronic HIV infection on COVID-19 Pfizer and Moderna RNA-based vaccine
immune responses to SARS-CoV-2 and the HIV reservoir. In Aim 1, we propose to conduct an in-
depth analysis of antibody neutralizing function and B lymphocyte responses in 100 male PWH and 100
female vaccinated PWH, and 25 male and 25 female vaccinated HUC, from the MWCCS. In Aim 2, we will
extensively characterize immune cell phenotypes, soluble markers, and functional cellular immune
responses to SARS-CoV-2 vaccination in the participants from Aim 1 before and after vaccination. In Aim 3,
we will evaluate the effects of COVID-19 vaccine on the persistent HIV reservoir (amount and composition,
immune parameters) before and after immunization. Aim 4 applies machine learning approaches on the
entire set of features quantified in Aims 1-3 to predict COVID-19 vaccine response outcomes and
determine the critical parameters that influence vaccine responses. We believe that this study is unique,
important, and critically timely for assessing the scientifically unprecedented, vaccine prevention
phase of the COVID-19 pandemic in the context of HIV infection.
Terms: <(TNF)-α><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><AIDS Virus><Ab response><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Affect><Anti-Retroviral Agents><Antibodies><Antibody Formation><Antibody Production><Antibody Response><Antibody titer measurement><Authorization><Authorization documentation><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><B.1.1.7><B.1.351><BNT 162b2><BNT162b2><Biological Markers><Booster Immunization><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 affected><COVID-19 consequence><COVID-19 crisis><COVID-19 effect><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 impact><COVID-19 impacted><COVID-19 pandemic><COVID-19 period><COVID-19 prevention><COVID-19 public health crisis><COVID-19 vaccination><COVID-19 vaccine><COVID-19 virus><COVID-19 years><COVID19 virus><CV-19><Cachectin><Cell Body><Cell Count><Cell Function><Cell Number><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><Chronic><Clinical><CoV-2><CoV2><Cohort Studies><Concurrent Studies><Coronavirus Infectious Disease 2019><Cytotoxic cell><Data><Data Set><Disease><Disorder><Exhibits><Female><Flu vaccination><Gene Transcription><Genetic Transcription><HBV Vaccination><HIV><HIV Infections><HTLV-III Infections><HTLV-III-LAV Infections><Health><Health Policy><Healthcare><Hep B vaccination><Hepatitis B Vaccination><Hepatitis B immunization><Hepatitis B injection><Hepatitis B series immunization><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Infections><IFN-Gamma><IFN-g><IFN-γ><IFNG><IFNγ><IgG1><IgG3><Immune><Immune Diseases><Immune Disorders><Immune Dysfunction><Immune Interferon><Immune Markers><Immune System Diseases><Immune System Disorder><Immune System Dysfunction><Immune System and Related Disorders><Immune response><Immunes><Immunity><Immunization><Immunocompetent><Immunodeficiency and Immunosuppression Disorders><Immunologic Diseases><Immunologic Markers><Immunological Diseases><Immunological Dysfunction><Immunological System Dysfunction><Immunological response><Individual><Inflammation><Influenza immunization><Influenza vaccination><Interferon Gamma><Interferon Type II><Investigation><K lymphocyte><LAV-HTLV-III><Long-Term Effects><Longitudinal Studies><Longterm Effects><Lymphadenopathy-Associated Virus><Machine Learning><Macrophage-Derived TNF><Measles><Measurable><Memory B Cell><Memory B-Lymphocyte><Modeling><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><Monocyte-Derived TNF><NK Cells><Natural Killer Cells><Outcome><Participant><Performance><Permission><Persons><Pfizer covid19 vaccine><Pfizer-BioNTech COVID-19 vaccine><Pfizer-BioNTech coronavirus disease 2019 vaccine><Pfizer/BioNTech vaccine><Phase><Phenotype><Prevention><Prophylactic vaccination against influenza><Public Health><RNA Expression><RNA vaccine><RNA-based vaccine><Recommendation><Research Resources><Resources><Rubeola><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.1.7><SARS-CoV-2 B.1.351><SARS-CoV-2 alpha><SARS-CoV-2 beta><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Secondary Immunization><Serology><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><South Africa strain><South Africa variant><South African><South African strain><South African variant><Spikevax><Subcellular Process><T-Cell Activation><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Transcription><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><U.K. variant><UK strain><UK variant><United Kingdom variant><United States><Vaccinated><Vaccination><Vaccinee><Vaccines><Viral Vector><Virus-HIV><Woman><Wuhan coronavirus><activate T cells><anti-retroviral><antibody biosynthesis><antibody titering><bio-markers><biologic marker><biomarker><booster vaccination><co-morbid><co-morbidity><cohort><comorbidity><coronavirus disease 2019><coronavirus disease 2019 consequence><coronavirus disease 2019 crisis><coronavirus disease 2019 effect><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 impact><coronavirus disease 2019 pandemic><coronavirus disease 2019 prevention><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 impact><coronavirus disease-19 pandemic><coronavirus disease-19 prevention><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><cytokine><cytotoxic><design><designing><flu immunisation><hCoV19><health care><health care policy><healthcare policy><hepatitis B virus vaccination><host response><hypoimmunity><immune competent><immune deficiency><immune response to vaccination><immune response to vaccines><immune system response><immune-based biomarkers><immunization against hepatitis B><immunodeficiency><immunogenicity><immunoglobulin biosynthesis><immunological biomarkers><immunological markers><immunoresponse><influenza virus vaccination><lFN-Gamma><long-term study><longitudinal outcome studies><longterm study><mRNA vaccine><mRNA-1273><mRNA-based vaccine><mRNA1273><machine based learning><male><men><morbilli><multiomics><multiple omics><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><neutralizing antibody><panomics><pathogen><predictive biomarkers><predictive marker><predictive molecular biomarker><prevent COVID-19><prevent coronavirus disease 2019><response><seroconversion><severe acute respiratory syndrome coronavirus 2 B.1.1.7><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><success><thymus derived lymphocyte><treatment trial><vaccinate against COVID-19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccinated individual><vaccinated participant><vaccinated patient><vaccinated person><vaccinated subject><vaccination against COVID-19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccination against hepatitis B><vaccination against influenza><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine associated immune response><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccine immune response><vaccine immunogenicity><vaccine induced immune response><vaccine response><vaccine responsiveness><vaccine study><vaccine trial><vaccine-induced response><vaccines preventing COVID><vaccines to prevent COVID><vector-based vaccine>